BACKGROUND: Commercial health plans may include corticosteroids in step therapy protocols for specialty drugs as part of use management. However, alignment with regulatory and clinical guidance is not...

Background To assess acceptability, feasibility, and effectiveness of incorporating individualized risk prediction into clinical assessment, decision making, and communication of risk of type 2 diab...

Featured podcasts by Leerink Partners – Sharing our insights and interviewing industry leaders to get their perspective.

This economic evaluation analyzes the costs and health outcomes of providing stable housing to people experiencing homelessness who have opioid use disorder (OUD).

AbstractObjectives. Cost-effectiveness thresholds inform whether health interventions represent good value for money, yet their use varies across countries

AbstractIntroduction. Health plan coverage policies determine specialty drug access and should reflect evolving standards of care; however, the timeliness

Specialty drugs, used to treat complex conditions such as cancer, autoimmune disorders, and rare diseases, including both biologics and high-cost small mol

YouTube video by Tufts-CEVR Cost-Effectiveness Analysis Registry

This cross-sectional study examines the association of drug prices and rebates with health plan coverage restrictions in the US.

BACKGROUND: Clinical outcome assessments (COAs) are tools widely used in clinical trials to evaluate treatment efficacy by capturing patient experience. However, little is known about how COAs are use...

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.

Background: Health plan policies managing neuromuscular disease (NMD) therapies may impose burdensome requirements on patients and providers. While prior resear...

Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.

AbstractIntroduction. The Inflation Reduction Act (IRA) authorizes Medicare price negotiation but includes a “special rule” deferring negotiation for biolo

Direct-to-patient programs offer a glimpse of an alternative future in which the consumer or the employer is brought closer to the manufacturer of the medicine prescribed.

The submission deadline is January 15th, 2026. Click next to proceed.

Subscription and open access journals from Sage, the world's leading independent academic publisher.

To compare 1-year healthcare costs and quality-adjusted life years (QALYs) for two diagnostic strategies in critically ill infants with suspected genetic disorders: 1) early rapid genome sequencing (w...

This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.

INTRODUCTION Older adults with dementia incur considerable out-of-pocket (OOP) health care expenses, but it is unclear how their financial burden differs by dementia stage. METHODS We identified 2...

Current methodological guidelines for value/health technology assessment (V/HTA) and cost-effectiveness analysis describe traditional approaches not originally created to be patient centered. The obje...

The Centers for Medicare and Medicaid Services (CMS) can now negotiate the prices of a set of drugs that represent significant Medicare expenditures. The long-term success of negotiations will depend ...

AbstractIntroduction. Prescription drug list prices, often cited in policy discussions, do not account for rebates negotiated between manufacturers and pay